Abstract: Described herein are synthetic glycan conjugates comprising a carrier and a glycan moiety derived from Neisseria meningitidis, wherein the glycan moiety is covalently linked to the carrier through a linker. Also provided herein are a mixture of the glycan conjugates thereof, immmunogenic compositions thereof, and kits thereof. The invention further provides methods of using the synthetic glycan conjugates and immunogenic compositions thereof to treat and/or reduce the risk of infectious diseases such as bacterial infections.

Abstract: The present invention is related to a process for reducing surface energy of a hole transport layer. The disclosed process comprises providing a hole transport layer; and providing a fluorine-containing layer directly on said hole transport layer. The configuration of said fluorine-containing layer reduces the structural disorder of an active layer and is able to recover a moisture-degraded hole transport layer, and thereby improves the performance of an electric device containing the same.

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and/or prostate cancer.

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.

Abstract: Apparatuses and methods for supercontinuum generation using a laser beam and a plurality of condensed state transparent plates are presented. As an example, plate material to be used for one of the plurality of plates is determined. A thickness of the one of the plurality of plates is also determined. An allowable laser intensity of the laser beam is then determined to be ?/(2n0n2L), where ? is the central incident wavelength in vacuum, n0 is the linear refractive index, n2 is the third-order nonlinear coefficient. A location of a next plate is then determined to be a distance downstream from the one of the plurality of plates where a laser intensity of the laser beam returns to a value of the determined allowable laser intensity.

Abstract: A sensing device applied to an analyte molecule of a liquid sample and a buffer flow has at least one first inlet, at least one second inlet, a micro-flow channel, and at least one immobilization element. The first inlet is for inputting the liquid sample. The second inlet is for inputting the buffer flow. The micro-flow channel communicates with the first inlet and the second inlet. The immobilization element is for immobilizing sensing molecules for the analyte molecules. The analyte sample flow and the buffer flow, in the reverse direction, in the micro-flow channel enable the association and disassociation kinetics to be obtained. The present invention further provides a sensing system and a sensing method using the sensing device.

Abstract: Methods and apparatuses for using microfluidics to generate bubbles and using the generated bubbles to construct scaffolds and cell-holding structures for culturing biological samples or analytes. In one implementation, a scaffold for growing cells is provided to include a matrix of interconnected cavities formed from mixing a gas and a liquid containing a cross linkable material to produce a matrix of gas bubbles of substantially the same size and cross linking the cross linkable material to form a structure in which cells are grown. In another implementation, a scaffold apparatus for growing cells includes a ball of a cross linked material forming an exterior shell that encloses to form a hollow interior inside the ball and biological samples embedded in the external shell.

Abstract: A combination of active agents selected from a FoxM1 enhancer, an Id1 enhancer, and a JNK3 inhibitor and the uses thereof in promoting cardiomyocyte proliferation and treating heart diseases in a subject in need of the treatment.

Abstract: Proteo-microparticles such as proteoliposomes comprising a microparticle (e.g., a liposome) and platelet membrane proteins, wherein the proteo-microparticles are capable of binding to monocytes, neutrophils, or other circulating blood cells capable of migrating to an injured site. Also provided herein are uses of the proteoliposomes for delivering a therapeutic agent via monocytes to an injured site.

Abstract: Bipartite molecules comprising a peptide affinity moiety and at least one charged moiety and uses thereof in reducing formation of abnormal protein aggregate and treating diseases associated with such abnormal protein aggregate, including neurodegenerative disease characterized by formation of protein aggregates.

Abstract: A method for enhancing wound healing or treating methicillin-resistant Staphylococcus aureus (MRSA) infection in a wound comprising administering a subject in need thereof with a therapeutically effective amount of a tilapia piscidin (TP) is described, wherein the TP is preferably TP3 or TP4.

Abstract: Methods for producing virus particles and viral antigens with simplified glycosylation profiles, such as mono-glycosylated forms of HIV, HCV, Dengue virus, West Nile virus and influenza virus. When used as targets for vaccine production, the conserved nature of such sites generate vaccines that are less sensitive to viral mutations. Such methods may include the use of glycosylation inhibitors for production of viruses or viral antigens with simplified glycosylation profiles.

Abstract: Methods for promoting maturation of cardiomyocytes, involving introducing a microRNA combination containing miR-125b, miR-199a, miR-221, and/or miR222, or suppression of ErbB4 in immature cardiomyocytes, which may be co-cultured with endothelial cells.

Abstract: Methods, systems, and devices are disclosed for molecular capture, manipulation, and analysis. In one aspect, a device to aggregate and characterize particles in a fluid includes an electrically insulative substrate including a channel to carry an electrically conducting fluid containing particles, electrodes located in the channel forming a nanoscale opening and including an insulating layer over their surface at the opening, a first circuit to apply a non-uniform ac electric field and a dc bias signal across the electrodes, in which the applied non-uniform ac electric field produces a positive dielectrophoretic force to aggregate the particles in a trapping region including the opening and adjacent region, a second circuit to detect changes in a dc current caused by at least some of the particles in the trapping region, and an optical device that directs a coherent light beam on the opening to determine Raman spectra of the particles in the trapping region.

Abstract: Provided herein are novel irreversible sialidase inhibitors. These compounds can be conjugated with a detectable tagging moiety such as azide-annexed biotin via CuAAC for isolation and identification of sialidases. The provided compounds and the corresponding detectable conjugates are useful for detecting sialidase-containing pathogens and imaging in situ sialidase activities under physiological conditions.

Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

Abstract: The present invention generally relates to a method for preparing induced mesenchymal stem cells (iMSCs) and its applications. The iMSCs, like MSCs, can differentiate into multiple lineages, which may be beneficial for disease treatments. In addition, the present invention also provides a method for improving the MSC's functional characteristics such that the MSCs are more suitable for cell therapy or in vitro applications.

Abstract: The preset invention relates to a new method or composition for treating a gastric ulcer, preventing or treating an infection of H. pylori, particularly multidrug resistant H. pylori, using an antimicrobial peptide, a functional derivate, fragment or variant thereof, wherein the antimicrobial peptide is selected from the group consisting of Epi-1, TPs and combination thereof.

Abstract: An indoor positioning system based on building design information is disclosed. The system includes a server computer to provide indoor position information relating to a building, a plurality of beacons to be installed in selected locations in the building and to broadcast by each beacon an indoor position message indicating the indoor position of the beacon, and an installer to configure the beacons with their corresponding indoor position information. An indoor positioning system development system is also provided. The development system incorporates building information files and provides a development interface for users to determine respective locations to install the beacons. Once completed, the obtained results are converted into an indoor position message for each beacon and configured in the corresponding beacon.

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating osteoporosis using such molecular constructs are also disclosed.